The relative bioavailability of terbutaline (Bricanyl) elixir and tablet formulations
Sitar, D.S.; Piafsky, K.M.; Ogilvie, R.I.
Current Therapeutic Research 19(2): 266-273
1976
ISSN/ISBN: 0011-393X
PMID: 813964
Accession: 041735176
PDF emailed within 1 workday: $29.90
Related References
E.S.attawy, H.; Kassem, A.; Zaghloul, A. 1997: Comparative kinetics and bioavailability of bioadhesives containing or not-containing ketoprofen tablet formulations relative to conventional tablet in humans Pharmaceutical Research (New York) 14(11 Suppl): S249Ahmed, I.S.; Fatahalla, F.A. 2007: Pilot study of relative bioavailability of two oral formulations of ketoprofen 25 mg in healthy subjects. A fast-dissolving lyophilized tablet as compared to immediate release tablet Drug Development and Industrial Pharmacy 33(5): 505-511
Degen, J.; Bruno, L.; Seiberling, M.; Schepers, C.; Brickl, R. 1992: Pharmacocinétique et biodisponibilité relative de deux formulations de dipyridamole (75 et 150 mg) après administration d'une prise unique orale à des volontaires sains - Pharmacokinetics and relative bioavailability of two tablet formulations (75 and 150 mg) of dipyridamole given as single dose to healthy male volunteers Comptes Rendus de Therapeutique et de Pharmacologie Clinique (108): 16-21
Lindfors, A.; Nyberg, E. 1989: Comparison of bricanyl sustained release pellets with bricanyl elixir in children with asthma Acta Paediatrica Scandinavica Suppl (359): 7
Korth-Bradley, J.M.; Parks, V.; Patat, A.; Matschke, K.; Mayer, P.; Fleckenstein, L. 2012: Relative Bioavailability of Liquid and Tablet Formulations of the Antiparasitic Moxidectin Clinical Pharmacology in Drug Development 1(1): 32-37
Wills, R.J.; Choma, N.; Buonpane, G.; Lin, A.; Keigher, N. 1987: Relative bioavailability of rimantadine HCl tablet and syrup formulations in healthy subjects Journal of Pharmaceutical Sciences 76(12): 886-888
Helmy, S.A. 2013: Pharmacokinetics and Relative Bioavailability Evaluation of Linezolid Suspension and Tablet Formulations Drug Research (Stuttgart 2013. Print) 63(9): 489-494
Nath, R.P.; Upton, R.A.; Everhart, E.T.; Cheung, P.; Shwonek, P.; Jones, R.T.; Mendelson, J.E. 1999: Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations Journal of Clinical Pharmacology 39(6): 619-623
Abou-Basha, L., I.; Wahman, L., F.; Gharib, H.A.; Tantway, W.H. 2005: Pharmacokinetic parameters and relative bioavailability of two tablet formulations of enalapril maleate Instrumentation Science and Technology 33(1): 1-8
Helmy, S.A. 2013: Pharmacokinetics and relative bioavailability evaluation of linezolid suspension and tablet formulations Drug Research 63(9): 489-494
Niopas, I.; Daftsios, A.C.; Xanthakis, I.; Nikolaidis, N. 2000: Relative bioavailability study of two nifedipine tablet formulations in healthy male volunteers International Journal of Clinical Pharmacology and Therapeutics 38(6): 309-314
Maas, B.; Garnett, W.R.; Comstock, T.J.; Pellock, J.M. 1985: Comparison of the relative bioavailability and pharmacokinetics of carbamazepine tablets and chewable tablet formulations Annals of Neurology 18(3): 379
Johnson, M.; Pene Dumitrescu, T.; Joshi, S.R.; Mathew, A.; Bainbridge, V.; Zhan, J.; Lataillade, M. 2022: Relative Bioavailability and Food Effect of GSK3640254 Tablet and Capsule Formulations in Healthy Participants Clinical Pharmacology in Drug Development 11(5): 632-639
Doose, D.R.; Walker, S.A.; Scott, V.V.; Boccumini, L.; Kotwal, P.; Thakur, M.; Baldassare, J. 1996: The comparative bioavailability of topiramate from two investigational pediatric sprinkle formulations relative to a tablet formulation Epilepsia 37(Suppl 5): 112
Fontes-Ribeiro, C.; Nunes, T.; Falcão, A.; Neta, C.; Lima, R.; Tavares, S.; Almeida, L.; Macedo, T.; Soares-da-Silva, P. 2005: Eslicarbazepine acetate (BIA 2-093) : relative bioavailability and bioequivalence of 50 mg/mL oral suspension and 200mg and 800mg tablet formulations Drugs in R&d 6(5): 253-260
Bagchus, W.M.; Bezuidenhout, D.; Harrison-Moench, E.; Kourany-Lefoll, E.; Wolna, P.; Yalkinoglu, O. 2019: Relative Bioavailability of Orally Dispersible Tablet Formulations of Levo- and Racemic Praziquantel: two Phase i Studies Clinical and Translational Science 12(1): 66-76
Chassard, D.; Legallicier, P.; Dib, M. 2003: Etude de la biodisponibilité relative de deux formulations orales d'acétate de chlormadinone : Lutéran® 5 mg et Lutéran® comprimé dosé à 10 mg - Relative bioavailability study of two formulations of chlormadinone acetate: Luteran® 5mg and Luteran® tablet dosed at 10mg Therapie (Paris) 58(2): 127-131
Niopas, I.; Daftsios, A.C.; Nikolaidis, N. 2001: Relative bioavailability of two isosorbide dinitrate sublingual tablet formulations administered as single doses in healthy subjects International Journal of Clinical Pharmacology and Therapeutics 39(5): 224-228
Cox, D.S.; Allred, A.; Zhou, Y.; Infante, J.R.; Gordon, M.S.; Bendell, J.; Jones, S.; Burris, H.; Orford, K. 2015: Relative bioavailability of pediatric oral solution and tablet formulations of trametinib in adult patients with solid tumors Clinical Pharmacology in Drug Development 4(4): 287-294
Song, Y.; Wang, X.; Perlstein, I.; Wang, J.; Badawy, S.; Frost, C.; LaCreta, F. 2015: Relative Bioavailability of Apixaban Solution or Crushed Tablet Formulations Administered by Mouth or Nasogastric Tube in Healthy Subjects Clinical Therapeutics 37(8): 1703-1712